磷脂酰肌醇蛋白聚糖-3作为肝细胞癌诊疗靶点
磷脂酰肌醇蛋白聚糖-3(GPC3)在多数肝细胞癌中高表达,在正常成人肝脏和肝硬化中无或极少表达,因此成为影像与治疗的理想分子靶点。早期放射性标记抗体PET成像验证了GPC3可视化的可行性,但完整抗体存在药代动力学局限;抗体片段、纳米抗体、单链可变片段和大环肽等新策略显著提高了早期时间点的成像对比度,并已开展首次人体PET研究。这些研究支持GPC3靶向放射性药物治疗的可行性,同时揭示了靶点表达的患者内和患者间异质性,强调治疗前需进行GPC3表达成像以筛选患者。
要点
- GPC3在多数肝细胞癌高表达、正常肝与肝硬化不表达,是诊疗一体化靶点。
- 抗体片段、纳米抗体和大环肽等小分子探针提高了GPC3 PET成像对比度。
- 靶点表达异质性要求治疗前GPC3成像筛选患者。
核心结论
- GPC3是肝细胞癌诊疗一体化有前景的分子靶点,治疗前GPC3表达成像有助于患者筛选和治疗监测。
研究设计与样本
- 本文为综述,汇总GPC3靶向抗体、抗体药物偶联物、细胞免疫治疗、分子影像剂和治疗性放射性药物的开发与临床研究进展。
主要发现
- 早期放射性标记抗体PET研究验证了GPC3可视化原理,但完整抗体用于肝脏成像存在药代动力学局限。
- 抗体片段、单域抗体、单链可变片段和大环肽等新策略在更早时间点显著改善成像对比度,并已在肝细胞癌和肝母细胞瘤患者中开展首次人体PET研究。
- 这些研究显示GPC3靶向放射性药物治疗可行,同时发现靶点表达存在患者内和患者间异质性。
关键数值与推荐
- 一项使用225Ac标记大环肽([225Ac]Ac-RAYZ-8009,RYZ801)的1期临床试验正在进行,采用[68Ga]Ga-RAYZ-8009(RYZ811)PET进行患者筛选。
- 一种225Ac标记的GPC3抗体BAY 3547926正在进行1/2期临床试验。
临床怎么用
- GPC3成像不仅可用于肝细胞癌的诊断和分期,还可用于治疗监测和GPC3靶向治疗的患者选择。
局限性
- GPC3靶点表达存在患者内和患者间异质性,可能影响靶向治疗的疗效和患者筛选。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Glypican-3 (GPC3) has emerged as an attractive molecular target for the imaging and therapy of hepatocellular carcinoma (HCC). It is highly expressed in most tumors but shows no or minimal expression in the normal adult liver and cirrhosis. This expression profile has stimulated the parallel development of GPC3-directed antibodies, antibody-drug conjugates, cellular immunotherapies, molecular imaging agents, and therapeutic radiopharmaceuticals. Early clinical imaging studies with radiolabeled antibodies established proof of principle that GPC3 can be visualized with PET imaging while also highlighting the pharmacokinetic limitations of full-size antibodies for liver imaging. More recent approaches using antibody fragments, single-domain antibodies, single-chain variable fragments, and macrocyclic peptides have substantially improved imaging contrast at earlier time points and have enabled first-in-human PET studies in patients with HCC and hepatoblastoma. These studies indicate the feasibility of GPC3-targeted radiopharmaceutical therapy but have also demonstrated intrapatient and interpatient heterogeneity of target expression, emphasizing the need for pretherapeutic imaging of GPC3 expression before therapeutic interventions. Thus, GPC3 imaging could contribute not only to the diagnosis and staging of HCC but also to treatment monitoring and the selection of patients for GPC3-targeted therapies. A clinical phase 1 trial with an 225Ac-labeled macrocyclic peptide ([225Ac]Ac-RAYZ-8009, RYZ801) using PET with [68Ga]Ga-RAYZ-8009 (RYZ811) for patient selection is currently ongoing. Furthermore, an 225Ac-labeled GPC3 antibody, BAY 3547926, is undergoing phase 1/2 clinical testing.
引用
- Weber WA, Eiber M, Lapa C, et al. Glypican-3 as a Theranostic Target in Hepatocellular Carcinoma. J Nucl Med. 2026. PMID: 42785950. doi:10.2967/jnumed.126.272814
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。